Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Suppor...
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients in U.K. with plans to expand to clinical sites...
ir.nurixtx.com